Company Description
Aspire Biopharma Holdings, Inc., an early-stage biopharmaceutical company, develops and markets disruptive technology for novel sublingual delivery mechanisms in the United States.
It offers sublingual aspirin product that is a soluble, PH neutral, and fast acting aspirin, which addresses cardiology emergencies and pain management.
The company is also developing formulations for sublingually administered products, such as melatonin sleep-aid product; vitamins D, E, and K; testosterone; and semaglutide product.
In addition, it is developing formulations for anti-nausea products, anti-psychotic products, ED drugs, seizure medication, and other classes of drugs through sublingual administration; and caffeine products, such as a formula for a single dose sublingual pre-workout supplement.
The company was founded in 2021 and is headquartered in Estero, Florida.
| Country | United States |
| Founded | 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Kraig Higginson |
Contact Details
Address: 23150 Fashion Drive, Suite 232 Estero, Florida 33928 United States | |
| Phone | 908 987 3002 |
| Website | aspirebiolabs.com |
Stock Details
| Ticker Symbol | ASBP |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001847345 |
| CUSIP Number | 738920305 |
| ISIN Number | US7389203057 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Kraig T. Higginson | Interim Chief Executive Officer, President and Executive Chairman of the Board |
| Ernest J. Scheidemann Jr. | Chief Financial Officer |
| Stephen E. Quesenberry | General Counsel and Corporate Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 15, 2026 | 10-Q | Quarterly Report |
| May 15, 2026 | SCHEDULE 13G | Filing |
| May 14, 2026 | 8-K | Current Report |
| May 13, 2026 | SCHEDULE 13G/A | Filing |
| May 12, 2026 | DEFR14A | Filing |
| May 8, 2026 | DEF 14A | Other definitive proxy statements |
| Apr 27, 2026 | PRE 14A | Other preliminary proxy statements |
| Apr 20, 2026 | 8-K | Current Report |
| Apr 17, 2026 | 8-K/A | [Amend] Current report |
| Apr 16, 2026 | 8-K | Current Report |